Ligand's Collaborator Merck Announces V116, An Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults, Met Key Immunogenicity And Safety Endpoints In Two Phase 3 Trials
Portfolio Pulse from Happy Mohamed
Ligand Pharmaceuticals (NASDAQ:LGND) and its collaborator Merck have announced positive results from two Phase 3 trials of V116, a 21-valent pneumococcal conjugate vaccine designed for adults. If approved, V116 would be the first of its kind. The vaccine uses Ligand's patent-protected Pelican Expression Technology™ platform, and Ligand is entitled to a royalty on worldwide net sales if the vaccine is approved.
July 27, 2023 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive Phase 3 trial results for V116, a vaccine developed in collaboration with Merck, could lead to approval and subsequent royalties for Ligand Pharmaceuticals.
The positive results from the Phase 3 trials of V116, a vaccine developed in collaboration with Merck, are a significant milestone for Ligand Pharmaceuticals. If the vaccine is approved, Ligand is entitled to a royalty on worldwide net sales, which could significantly boost the company's revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100